Sellas Life Sciences Group Inc SLS:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 7:34 PM EDT8.08
-0.11 (-1.34%)
-0.11 (-1.34%)Volume
99,695
Close
8.19-0.14 (-1.68%)
-0.14 (-1.68%)Volume
7,161,331
52 week range
1.39 - 9.51
- Open8.12
- Day High8.28
- Day Low7.85
- Prev Close8.33
- 52 Week High9.51
- 52 Week High Date05/29/26
- 52 Week Low1.39
- 52 Week Low Date12/02/25
Latest On Sellas Life Sciences Group Inc
Key Stats
- Market Cap1.524B
- Shares Out186.03M
- 10 Day Average Volume13.40M
- Dividend-
- Dividend Yield-
- Beta2.53
Latest On Sellas Life Sciences Group Inc
KEY STATS
- Open8.12
- Day High8.28
- Day Low7.85
- Prev Close8.33
- 52 Week High9.51
- 52 Week High Date05/29/26
- 52 Week Low1.39
- 52 Week Low Date12/02/25
- Market Cap1.524B
- Shares Out186.03M
- 10 Day Average Volume13.40M
- Dividend-
- Dividend Yield-
- Beta2.53
RATIOS/PROFITABILITY
- EPS (TTM)-0.23
- P/E (TTM)-35.21
- Fwd P/E (NTM)-51.19
- EBITDA (TTM)-31.463M
- ROE (TTM)-43.58%
- Revenue (TTM)-
- Gross Margin (TTM)90.00%
- Net Margin (TTM)-4,130.10%
- Debt To Equity (MRQ)-
EVENTS
- Earnings Date08/10/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MORESELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer...
John Varian
Independent Chairman of the Board
Angelos Stergiou M.D.
President, Chief Executive Officer, Director
John Burns CPA
Chief Financial Officer, Senior Vice President
Address
7 TIMES SQUARE, SUITE 2503
New York, NY
10036
United States